Venture capital has the brains, private equity has the books – can they make lots of money?
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
New devices are coming, but the real advances will involve combinations.
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Novel approaches including gene editing are creeping towards approval.